QUANTUM GENOMICS : Quantum Genomics at J.P. Morgan 34th annual healthcare conference
Massy - January 12, 2015
Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces its presence at J.P. Morgan 34 th annual healthcare conference taking place from January 12 to January 15, 2015, in San Francisco, California (USA).
This conference is one of the largest annual events allowing biotechnology/life science companies to meet with investors and firms of the pharmaceutical and health industry.
At this event, Quantum Genomics management will give an update on the progress of the various research programs of the company, in particular the ANSM (French Drug Administration) and PPC (Protection of Persons Committee) approvals at the end of 2014 to initiate Phase II trials for QGC001, first-in-class drug candidate to treat hypertension.
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than twenty years of academic research that has taken place in the laboratories of the Collège de France, INSERM and CNRS.
Quantum Genomics is listed on Alternext in Paris (ISIN code: FR0011648971 - ticker ALQGC).
More informations: www.quantum-genomics.com
Contacts
|
Quantum Genomics
Lionel Ségard CEO (+33) 1 60 13 76 80 |
Quantum Genomics
Marc Karako CFO - Investor relations (+33) 1 60 13 76 84 marc.karako@quantum-genomics.com |
ACTUS
Jean-Michel Marmillon Press relations (33) 1 53 67 36 73 jmmarmillon@actus.fr |
Information réglementée
Communiqués au titre de l'obligation d'information permanente :
- Autres communiqués
Communiqué intégral et original au format PDF :
http://www.actusnews.com/documents_communiques/ACTUS-0-38445-QGC_PR_JPMORGAN-HEALTH-20150112_UK.pdf